본문 바로가기
KERD
논문KCI 등재

A Phase II Trial of Docetaxel and Ifosfamide for Patients with Platinum-Resistant or Refractory Non-Small Cell Lung Cancer in a Salvage Setting

이종석|Gyeong-Won Lee|Jung-Hun Kang|Ho-Cheol Kim|Won-Sup Lee|Jong-Duk Lee|Joung-Soon Jang|Hea Yong Lee|Young-Sil Hwang|Seok-Hyun Kim
대한암학회 (Korean Cancer Association)|2004.10|Cancer Research and Treatment|제36권 제5호|pp. 287-292

2

조회

0

다운로드

0

인용

0

참고문헌

주제분류의학일반

초록

Abstract

Purpose: We conducted a phase II study of docetaxel and ifosfamide chemotherapy for patients with platinum- resistant or refractory non-small-cell lung cancer (NSCLC) to evaluate the response and toxicity profiles as a salvage treatment. Materials and Methods: Between July 2000 and July 2004, 40 patients who had previously received platinum- based regimen as the first-line or second-line therapy were enrolled in this study. The treatment consisted of a docetaxel 75 mg/m2 intravenous infusion on day 1 and intravenous ifosfamide 3 g/m2 with Mesna uroprotectione on day 1 through 3. This regimen was repeated every 3 weeks. Results: One hundred thirty cycles of treatment were given, with a median of 3 cycles (range: 2~6 cycles). All the patients were evaluable for the response rate and toxicity profile. The major toxicity was myelosuppression. Grade 3~4 neutropenia occurred in 30 patients (75%) during treatment. Febrile neutropenia occurred in 16 patients (40%). Five of 40 patients (12.5%) had a partial response (95% confidence interval, 3.3~21.7%). The median time to disease progression was 2.65 months (range: 2.02~3.20 months), and the median survival was 5.24 months (range: 2.99~7.49 months). Conclusion: Salvage chemotherapy with docetaxel and ifosfamide showed a low efficacy and a high proportion of severe neutropenia in patients with platinum-resistant or refractory advanced NSCLC.(Cancer Res Treat. 2004;36:287-292)

참고문헌 (24)

  1. "Survival of Korean cancer patients diagnosed in 1995;134Korean Cancer Registry-affiliated Hospitals", 34, pp.319~325 (2002)
  2. "Chemotherapy fornon-small-cell lung cancer:The continuing challenge", 99, pp.1326~1328 (1991)
  3. "The use of docetaxel(Taxotere)inpatients with advanced non-small cell lung cancer previouslytreated with platinum-containing chemotherapyregimens", 26, pp.9~12 (1999)
  4. "Randomized phase III trial of docetaxel versus vinorelbineor ifosfamide in patients with advanced non-small celllung cancer previously treated with platinum-containingchemotherapy regimens", 18, pp.2354~2362 (2000), The TAX 320 Non-Small CellLung Cancer Study Group.
  5. "Prosepctive randomizedtrial of docetaxel versus best supportive care in patientswith non-small-cell lung cancer previously treated withplatinum-based chemotherapy", 18, pp.2095~2103 (2000)
  6. "Phase III randomized trial comparing cisplatinand carboplatin with or without ifosfamide in patients withadvanced non-small-cell lung cancer", 16, pp.1388~1396 (1998), European LungCancer Working Party
  7. "Overview of ifosfamide in small cell andnon-small cell lung cancer", 6, pp.87~98 (1990)
  8. "A phse II randomized studywith cisplatin and etoposide as the control arm", pp.2631~4
  9. "Phase I study on docetaxel and ifosfamidein patients with advanced solid tumors Br", 77, pp.153~158 (1998)
  10. "The WHO Handbook forreporting the results of Cancer Treatment" (1979)
  11. "How large should a phase II trial of a new drugbe", pp.1079~1085
  12. "Anoverview of current results with the gemcitabine anddocetaxel combination as initial and salvage chemotherapyregimen in advanced non-small cell lung cancer", 45, pp.265~275 (2003)
  13. "Phase II study of docetaxel for advanced or metastaticplatinum-refractory non-small-cell lung cancer", 13, pp.645~651 (1995)
  14. "Activity ofdocetaxel in platinum-treated non-small-cell lung cancer:results of a phase II multicenter trial", 18, pp.131~135 (2000)
  15. "Assembly of purified GDP-tubulininto microtubule induced by taxol and taxotere:reversibility,ligand stoichiometry,and completition", 32, pp.2747~2755 (1993)
  16. "Bcl2 is the guardian of microtubuleintegrity", 57, pp.229~233 (1997)
  17. "is an active in non-small cell lungcancer a Phase II trial of the EORTC Early Clinical TrialsGroup", pp.384~387
  18. "Phase II Trial of docetaxel inpatients with stage III and IV non-small-cell lung cancer", 12, pp.1232~1237 (1994)
  19. "Preclinical phase II study of ifosfamide in humantumor xenografts in vivo", 26, pp.7~11
  20. "Ifosfamide and docetaxelin non-small cell lung cancer", 25, pp.29~37 (1998)
  21. "A preclinical model forexperiemental chemotherapy of human head and neckcancer", 18, pp.1145~1149 (2001)
  22. "Docetaxel and ifosfamide as second-line treatment forpatients with advanced or metastatic urothelial cancer afterfailure of platinum chemotherapy:a phase 2 study", 165, pp.67~71 (2001)
  23. "A phase I", II trialof cisplatin, docetaxel and ifosfamide in advanced orrecurrent non-small cell lung cancer, 2001, pp.33, 259~265
  24. "Phase II study of docetaxel and ifosfamidecombination chemotherapy in non-small-cell lung cancerpatients failing previous chemotherapy with or withoutpaclitaxel", 39, pp.209~214 (2003)

관련 논문AI추천

The Safety and Efficacy of Second-line Single Docetaxel (75 mg/m2) Therapy in Advanced Non-Small Cell Lung Cancer Patients who were Previously Treated With Platinum-based ChemotherapyByoung Yong Shim, Chi Hong Kim, Deog Gon Cho, Eun Jung Hong, Hoon-Kyo Kim, Jinyoung Yoo, Kyu Do Cho, Meyung Im Ahn, Min Seop Jo, So Hyang Song, Sung Whan Kim, Suzy Kim대한암학회 · Cancer Research and Treatment2005 · 제37권 제6호Effect of Vinorelbine, Ifosfamide and Cisplatin Combination Chemotherapy in Stage III-IV Non-Small-Cell Lung CancerChi Hong Kim, Deng Gon Cho, Hong Joo Cho, Hoon Kyo Kim, Jin Hyung Kang, Jinyoung You, Jung A Kim, Kyu Do Cho, Meyung Im Ahn, So Hyang Song, So Young Lee, Sung Whan Kim, Young Chul Kim대한암학회 · Cancer Research and Treatment2002 · 제34권 제5호Efficacy and Safety Study of Docetaxel as Salvage Chemotherapy in Metastatic Gastric Cancer Failing Fluoropyrimidine and Platinum Combination ChemotherapyByung Sik Kim, Heung Moon Chang, Jae-Lyun Lee, Jeong Hwan Yook, Jung Shin Lee, Min-Hee Ryu, Sung Tae Oh, Tae-Won Kim, Yoon-Koo Kang대한암학회 · Cancer Research and Treatment2005 · 제37권 제4호Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer: Past, Present, and Hope for the Future박근칠대한암학회 · Cancer Research and Treatment2003 · 제35권 제4호Preliminary Results of Paclitaxel, Cisplatin and Concurrent High-Dose Radiation Therapy for Locally AdvancedNon-Small-Cell Lung Cancer김동순, 김상위, 김우성, 김원동, 김종훈, 노영주, 서철원, 안승도, 오석중, 이상도, 이상욱, 이정신, 최은경, Kyoung Ju Kim대한암학회 · Cancer Research and Treatment2002 · 제34권 제5호A Phase II Study of Gemcitabine Monotherapy in Breast Cancer Patients Refractory to Anthracycline and TaxaneChul Kim, Gwi Eon Kim, Hyun Cheol Chung, Joo Hyuk Sohn, Jun Yong Park, Sun Young Rha, Woo Ick Jang, Yong Tae Kim대한암학회 · Cancer Research and Treatment2002 · 제34권 제4호

이 간행물의 다른 논문 (9건)

Transcription Factors in the Cellular Signaling Network as Prime Targets of Chemopreventive PhytochemicalsYoung-Joon Surhpp. 275-286A Phase II Study of Weekly Paclitaxel, Cisplatin and Concurrent Radiation Therapy for Locally-Advanced Unresectable Non-Small Cell Lung Cancer: Early Closure due to Lack of Efficacy경선영, 이재웅, 조은경, 임영희, 정성환, 이규찬, 방수미, 이재훈, 안창혁, 김미경, 신동복, 박정웅, 박세훈pp. 293-297Prognostic Significance of CD24 Expression in Gastric Carcinoma김우호, Nevine S. Darwish, Yong Il Kim, 이병란, 김민아, 장미수, 이혜승pp. 298-302Expression of Caspase-3 and c-myc in Non-Small Cell Lung Cancer김훈교, 조덕곤, 안명임, 조규도, 김치홍, 김수지, 강석진, 조민섭, 조홍주, 정윤주, 송소향, 심병용, 유진영pp. 303-307Effective Inhibition of Cancer Cell Growth by a Novel Tripartite Transfection Complex Containing Ribbon Antisense Molecules to hTRJong-Gu Parkpp. 308-314
원문 보기